Therapeutic aspects of hepatitis C in hemodialysis patients

American Journal of Nephrology

Volumn 29, Issue 2, 2009, Pages 123-128

  Hosseini Moghaddam, Seyed Mohammadmehdi ^a,c   Alavian, Seyed Moayed ^b   Rahnavardi, Mohammad ^a  

^a SHAHID BEHESHTI UNIVERSITY   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNRC   (Iran)

Author keywords

Dialysis; Hepatitis C virus; Kidney failure

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOPENIA; MONOTHERAPY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; THROMBOCYTOPENIA; VIROLOGY;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 49849092449     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151633     Document Type: Article

References (49)

1. Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
2. Canavese C, Hollo Z, Ciccone G, Ghisetti V, Barbui A, Fop F, Martina G, Forgnone F, Novo P, Thea A, Grill A, Marchiaro G: Extrahepatic immunological manifestations of hepatitis C virus in dialysis patients. J Nephrol 2000;13:352-359.
3. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432.
4. Yee HS, Currie SL, Darling JM, Wright TL: Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2006;101:2360-2378.
5. Alavian SM: Optimal therapy for hepatitis C. Hepatitis Monthly 2004;4:41-42.
6. Alavian SMM, Asl MA, Keshvari M, Behnava B, Hajibeigi B: Efficacy and safety of interferon-alpha (PDferon B®) and ribavirin combination therapy in patients with chronic hepatitis C in Iran. Hepatitis Monthly 2006;6:11-18.
7. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S: Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000;68:556-567.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
10. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
11. Magnone M, Holley JL, Shapiro R, Scantlebury V, McCauley J, Jordan M, Vivas C, Starzl T, Johnson JP: Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995;59:1068-1070.
12. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D: Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995;59:1426-1431.
13. Kamar N, Ribes D, Izopet J, Rostaing L: Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation 2006;82:853-856.
14. Huraib S, Iqbal A, Tanimu D, Abdullah A: Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 2001;21:435-440.
15. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, Rostaing L: Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003;14:2092-2098.
16. Gonzalez-Roncero F, Gentil MA, Valdivia MA, Algarra G, Pereira P, Toro J, Sayago M, Mateos J: Outcome of kidney transplant in chronic hepatitis C virus patients: effect of pretransplantation interferon-alpha2b monotherapy. Transplant Proc 2003;35:1745-1747.
17. Younossi ZM, Braun WE, Protiva DA, Gifford RW Jr, Straffon RA: Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation 1999;67:272-275.
18. Einollahi B, Hajarizadeh B, Bakhtiari S, Lesanpezeshki M, Khatami MR, Nourbala MH, Pourfarziani V, Alavian SM: Pretransplant hepatitis C virus infection and its effect on the post-transplant course of living renal allograft recipients. J Gastroenterol Hepatol 2003;18:836-840.
19. Kliem V, van den Hoff U, Brunkhorst R, Tillmann HL, Flik J, Manns MP, Pichlmayr R, Koch KM, Frei U: The long-term course of hepatitis C after kidney transplantation. Transplantation 1996;62:1417-1421.
20. Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr: Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003;98:1610-1615.
21. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P: Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003;18:1071-1081.
22. Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, Pascal JP, Durand D, Canal P: Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998;9:2344-2348.
23. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, Degott C, Carnot F, Riffaud PC, Chevret S: The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001;16:1017-1023.
24. Rocha CM, Perez RM, Ferreira AP, Carvalho-Filho RJ, Pace FH, Silva IS, Pestana JO, Lanzoni VP, Silva AE, Ferraz ML: Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006;26:305-310.
25. Rivera M, Gentil MA, Sayago M, Gonzalez Roncero F, Trigo C, Algarra G, Pereira P, Valdivia MA, Aguilar J: Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant. Transplant Proc 2005;37:1424-1425.
26. Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano TT, Casanova A, Perez JL, Guerrero L, Gonzalez MT, Andres E, Gil-Vernet S, Casais LA: Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001;96:1170-1177.
27. Gürsoy M, Gur G, Arslan H, Ozdemir N, Boyacioglu S: Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 2001;8:70-77.
28. Urbanek P, Tesar V, Prochazkova-Francisci E, Lachmanova J, Marecek Z, Svobodnik A: Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon-alpha. Treatment of hepatitis C. Blood Purif 2004;22:344-350.
29. Izopet J, Sandres-Saune K, Kamar N, Salama G, Dubois M, Pasquier C, Rostaing L: Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol 2005;77:70-76.
30. Campistol JM, Esforzado N, Martinez J, Rosello L, Veciana L, Modol J, Casellas J, Pons M, de Las Cuevas X, Piera J, Oliva JA, Costa J, Barrera JM, Bruguera M: Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999;14:2704-2709.
31. Huraib S, Tanimu D, Romeh SA, Quadri K, Al Ghamdi G, Iqbal A, Abdulla A: Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 1999;34:55-60.
32. Hanrotel C, Toupance O, Lavaud S, Thiefin G, Brodard V, Ingrand D, Diebold MD, Wynckel A, Chanard J: Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001;88:120-126.
33. Casanovas Taltavull T, Baliellas C, Sese E, Iborra MJ, Benasco C, Andres E, Gonzalez MT, Gil-Vernet S, Casanova A, Casais LA: Interferon may be useful in hemodialysis patients with hepatitis C virus chronic infection who are candidates for kidney transplant. Transplant Proc 1995;27:2229-2230.
34. Grgurevic I, Vince A, Buljevac M, Banic M, Jeren-Strujic B, Kes P, Kujundzic M, Leko N, Lukic IK, Slavicek J: Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients: two therapeutic protocols compared. Nephron Clin Pract 2006;103:c8-c11.
35. Espinosa M, Rodriguez M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Lopez-Rubio F, de la Mata M, Aljama P: Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 2001;55:220-226.
36. Tan AC, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, de Vries RA, Vroom B: Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001;16:193-195.
37. Bruchfeld A, Ståhle L, Andersson J, Schvarcz R: Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2001;16:1729.
38. Bruchfeld A, Ståhle L, Andersson J, Schvarcz R: Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hepat 2001;8:287-292.
39. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA: Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004;36:1831-1834.
40. Martin P, Mitra S, Farrington K, Martin NE: Pegylated 40 kDa interferon alfa-2a Pegasys is unaffected by renal impairment. Hepatology 2000;32:370A.
41. Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, Sack M, Glue P, Jacobs S, Affrime M: Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002;42:1109-1115.
42. Lamb MW, Marks IM, Modi MW, Preston RA, Pappas SC: Peginterferon alfa-2a (40 kD) (Pegasys) can be administered safely in patients with end-stage renal disease. Hepatology 2001;34:326.
43. Covic A, Maftei ID, Mardare NG, Ionita-Radu F, Totolici C, Tuta L, Golea O, Covic M, Volovat C, Gusbeth-Tatomir P, Mircescu G: Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 2006;19:794-801.
44. Russo MW, Ghalib R, Sigal S, Joshi V: Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006;21:437-443.
45. Kokoglu OF, Ucmak H, Hosoglu S, Cetinkaya A, Kantarceken B, Buyukbese MA, Isik IO: Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006;21:575-580.
46. Sporea I, Popescu A, Sirli R, Golea O, Totolici C, Danila M, Vernic C: Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 2006;12:4191-4194.
47. Teta D, Luscher BL, Gonvers JJ, Francioli P, Phan O, Burnier M: Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 2005;20:991-993.
48. Chan TM, Ho SK, Tang CS, Tse KC, Lam MF, Lai KN, Yung S: Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology (Carlton) 2007;12:11-17.
49. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R: Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006;13:316-321.